In medical genetics, “mannosyltransferases” are enzymes that add the sugar mannose during the early building steps of N-linked glycosylation—a process cells use to decorate many proteins with sugar chains so they fold, move, and work correctly.
The phrase “mannosyltransferase 7–9 deficiency” is not a standard diagnosis? name. Clinicians usually mean defects in the mannosyltransferase steps that act when the growing sugar chain has seven, eight, or nine mannose units. Those steps are carried out mainly by two enzymes:

• ALG12 (α-1,6-mannosyltransferase): adds a mannose to a chain with seven mannoses (Man7) to make Man8. Deficiency causes ALG12-CDG (historical name CDG-Ig). PMC+1

• ALG9 (α-1,2-mannosyltransferase): adds mannose at more than one early step and is also required to reach Man9. Deficiency causes ALG9-CDG (historical name CDG-Il). Orpha.net+2PMC+2

Important: the gene ALG7 (human DPAGT1) is not a mannosyltransferase; it performs an earlier GlcNAc-transferase step. Its disorder is DPAGT1-CDG, not a “mannosyltransferase deficiency.” I note this only to avoid mix-ups created by the similar numbering. NCBI+1

This guide focuses on ALG12-CDG and ALG9-CDG, because these are the recognized mannosyltransferase defects at the Man7–Man9 stage.

Other names

• ALG12-CDG (historical CDG-Ig; “ALG12 mannosyltransferase defect”) PubMed

• ALG9-CDG (historical CDG-Il; “ALG9 α-1,2-mannosyltransferase defect”) Orpha.net+1

• Congenital? disorder of glycosylation, type I due to ALG12 or ALG9 (both are type-I CDGs, affecting lipid-linked oligosaccharide assembly). Yeast Genome Database

Mannosyltransferase 7–9 deficiency (understood as ALG12-CDG and ALG9-CDG) is a rare, inherited metabolic disease. Because of a spelling error in one of the “sugar-adding” enzymes, cells cannot finish building the nine-mannose starter sugar that must be attached to many new proteins in the endoplasmic reticulum. As a result, many proteins get incomplete or abnormal sugar chains, making them unstable or poorly functional. This mismatch affects many organs at once, especially the brain, muscles, liver, heart, and kidneys. Symptoms usually start in infancy or early childhood and vary widely from mild learning problems to significant disabilities. There is no single cure yet; care focuses on treating symptoms, supporting development, and preventing complications. PMC+2Orpha.net+2

Types

1. ALG12-CDG (CDG-Ig): due to pathogenic variants in ALG12, which adds a mannose to Man7 to make Man8. Typical features can include developmental delay, low muscle tone, facial differences, coagulation problems, organ involvement, and sometimes eye findings. PMC+1

2. ALG9-CDG (CDG-Il): due to pathogenic variants in ALG9, which helps extend the chain toward Man9. Reported features include progressive microcephaly (small head size), severe developmental delay, drug-resistant seizures, characteristic facial features, mild cardiac defects, and cystic kidneys in some patients. Orpha.net+1

3. DPAGT1-CDG (ALG7/“7”) – usually severe neurologic disease (hypotonia, seizures, microcephaly) in infancy; a subset presents as congenital? myasthenic syndrome with fatigable weakness? that may respond to cholinesterase inhibitors. National Organization for Rare Disorders+2PMC+2

4. ALG8-CDG (“8”) – multisystem illness with hypotonia, hepatomegaly, coagulopathy, edema?/ascites, diarrhea?, respiratory issues, and occasionally cataracts. BioMed Central+1

5. ALG9-CDG (“9”) – rare; developmental delay, seizures, dysmorphism, mild heart defects, liver disease, and polycystic kidneys in several reports. PMC

(Scientists also describe other mannosyltransferase defects earlier in the pathway—e.g., ALG11-CDG—but these act before the Man7–Man9 stage and are listed here only for context.) PubMed

Causes

Each item below is written as a brief plain-language paragraph.

1. Biallelic pathogenic variants in ALG12. A child inherits one faulty copy from each parent; together they reduce ALG12 activity and block the Man7→Man8 step. PubMed

2. Biallelic pathogenic variants in ALG9. Two harmful ALG9 changes impair α-1,2-mannose additions needed to reach Man9. Orpha.net+1

3. Missense mutations (wrong amino acid). A single “letter change” can alter the enzyme’s shape, slowing its work. Both ALG12 and ALG9 cases include missense variants. PubMed+1

4. Nonsense/frameshift mutations (truncated protein). Early stop signals or small insertions/deletions can produce a shortened, non-working enzyme. PubMed

5. Splice-site mutations. Changes at exon–intron boundaries can produce mis-spliced mRNA and unstable enzyme. PubMed

6. Compound heterozygosity. Two different harmful variants, one on each allele, together cause disease. PMC

7. Variants affecting catalytic residues. Changes in key active-site amino acids directly reduce transferase activity. (Shown across ALG mannosyltransferases.) ScienceDirect

8. Variants disrupting ER targeting or topology. These enzymes are multi-pass ER membrane proteins; mislocalization reduces function. ScienceDirect

9. Reduced availability of donor sugar (Dol-P-Man). If the cell struggles to make dolichyl-phosphate-mannose, even normal ALG9/ALG12 can be “functionally starved,” worsening a mild genotype. (Mechanistic principle in LLO assembly.) Yeast Genome Database

10. ER quality-control degradation. Misfolded ALG9/ALG12 proteins may be degraded by ER-associated pathways, lowering enzyme levels. ScienceDirect

11. Founder variants in small populations. Recurrent pathogenic changes can cluster in specific groups, increasing risk for carrier couples. (Observed across multiple CDGs.) BioMed Central

12. Consanguinity/related parents. Increases the chance a child receives the same rare variant from both parents. (General CDG risk factor.) BioMed Central

13. Large deletions/duplications. Copy-number changes removing critical exons can abolish enzyme production. (Detected on exome/array testing in CDG cohorts.) PMC

14. Promoter/UTR variants. Regulatory changes can reduce mRNA levels and enzyme quantity. (Documented mechanisms in glycosylation genes.) ScienceDirect

15. Dominant-negative rare scenarios. A mutant subunit (or misassembled complex) can interfere with residual function; rare but possible in membrane enzymes. ScienceDirect

16. Stressors that increase protein demand. Fever?/illness can unmask a marginal pathway by increasing throughput needs for glycoprotein folding. (Known phenomenon in ER glycosylation disorders.) Yeast Genome Database

17. Unfolded protein response (UPR) overload. Chronic? ER stress from mis-glycosylated proteins may secondarily suppress glycosylation enzymes. ScienceDirect

18. Second-site genetic modifiers. Variants in other glycosylation genes can worsen or soften the phenotype. (Reported across CDG families.) PMC

19. Mosaicism in a transmitting parent. Rarely, a parent with low-level gonadal mosaicism can pass on a pathogenic allele, explaining unexpected recurrence. (General genetic principle in rare diseases.) PMC

20. De novo variant plus inherited carrier allele. Very uncommon in autosomal-recessive disease, but possible if one allele arises new in the child. (Illustrated in CDG case series.) PMC

Symptoms and signs

Severity varies a lot; not every person has every feature.

1. Developmental delay and learning difficulties. Common across CDGs due to global protein-processing problems in the brain. Orpha.net

2. Low muscle tone (hypotonia). Babies may feel “floppy,” with delayed head control and sitting. Orpha.net

3. Seizures (sometimes hard to control). Particularly emphasized in ALG9-CDG cohorts. Orpha.net

4. Progressive microcephaly. Head growth can slow over time in ALG9-CDG. Orpha.net

5. Characteristic facial features. Reported patterns help doctors consider a CDG, including in ALG12-CDG. Orpha.net

6. Feeding difficulties and failure to thrive. Poor weight gain is frequent in infancy. BioMed Central

7. Liver involvement. Enlarged liver, abnormal liver enzymes, and sometimes protein-losing enteropathy in related early LLO defects. BioMed Central

8. Coagulation problems. Abnormal clotting tests or a tendency to bleed due to mis-glycosylated coagulation proteins (noted in early LLO CDGs including ALG12). BioMed Central

9. Cardiac findings (often mild). Mild structural or rhythm issues have been described in ALG9-CDG. PMC

10. Kidney cysts (polycystic kidneys). Reported in several ALG9-CDG patients. PMC

11. Recurrent infections. Weakened glycoprotein function can impair immune responses in some CDGs. BioMed Central

12. Eye issues. Cataracts have been reported across early LLO synthesis defects (including ALG12 in some series). BioMed Central

13. Growth restriction/short stature. Multi-system illness and feeding issues contribute. BioMed Central

14. Motor incoordination/ataxia. Cerebellar involvement is common across many type-I CDGs. Yeast Genome Database

15. Edema?/ascites (fluid accumulation). Seen in severe neonatal presentations of early LLO defects. BioMed Central

Diagnostic tests

A) Physical-exam based evaluations

1. General pediatric/neurologic exam. Looks for hypotonia, delayed milestones, reflex patterns, and head-growth curves that suggest a systemic? disorder. Orpha.net

2. Dysmorphology assessment. Trained clinicians note facial/body patterns linked to specific CDGs (e.g., ALG12-CDG). Orpha.net

3. Growth and nutrition review. Weight, length/height, head circumference, and feeding/aspiration signs guide urgency and support needs. BioMed Central

4. Organ system screening?. Bedside checks for hepatomegaly, edema?, heart murmurs, and signs of dehydration? or ascites. BioMed Central

B) Manual/bedside functional testing

5. Developmental screening? tools (e.g., Bayley, Denver). Structured tasks measure motor, language, and social skills over time. (Standard in neurodevelopmental disorders.)

6. Bedside coordination tests (finger-to-nose, heel-to-shin). Detect ataxia or cerebellar signs common in CDGs. Yeast Genome Database

7. Swallow evaluation by speech-language therapist. Assesses feeding safety and need for thickening or tube feeding in hypotonic infants. (Standard supportive practice.)

C) Laboratory and pathological testing

8. Transferrin isoelectric focusing (TIEF). A frontline screening? test: abnormal “type-I” transferrin pattern suggests a defect in early N-glycosylation steps like ALG12/ALG9. PMC

9. Transferrin glycoform mass spectrometry. More precise confirmation of glycosylation defects and subtype patterns. (Modern alternative to TIEF.) PMC

10. Serum N-glycan profiling. Broad look at released glycans; incomplete high-mannose chains support a type-I CDG. (Used in specialty labs.) PMC

11. Liver function tests and coagulation panel. Tracks hepatopathy and clotting factor glycosylation effects seen in early LLO CDGs. BioMed Central

12. Creatine kinase (CK) and metabolic panel. Elevations may reflect muscle stress; panel monitors nutrition, electrolytes, and organ status. (Supportive monitoring.)

13. Genetic testing—CDG gene panel or exome/genome. Detects ALG12 or ALG9 pathogenic variants; parental testing clarifies inheritance. Orpha.net+1

14. Sanger sequencing for confirmation. Verifies suspected variants found on next-generation tests (clinical genetics standard).

15. Enzyme/biochemical studies in fibroblasts (research/specialty). Directly measures mannosyltransferase activity or analyzes lipid-linked oligosaccharides; in ALG12-CDG, Man7 accumulates because the Man7→Man8 step is blocked. PMC+1

D) Electrodiagnostic studies

16. EEG (electroencephalogram). Documents seizure? types and guides antiseizure therapy; seizures can be drug-resistant in ALG9-CDG. Orpha.net

17. EMG/nerve-conduction studies (when indicated). Evaluate peripheral nerve involvement contributing to hypotonia or weakness?. (Used selectively in CDGs.)

E) Imaging

18. Brain MRI. Looks for structural changes that correlate with development and seizures (e.g., cerebellar changes seen across type-I CDGs). Yeast Genome Database

19. Echocardiogram. Screens for the mild cardiac defects reported in ALG9-CDG. PMC

20. Renal? ultrasound?. Checks for polycystic kidneys associated with ALG9-CDG. PMC

Non-pharmacological treatments (therapy and other supports)

There is currently no proven curative, targeted sugar therapy for ALG7/DPAGT1-, ALG8-, or ALG9-CDG. Most care is supportive and multidisciplinary (genetics, neurology, nutrition, PT/OT/SLP). Mannose therapy is effective in MPI-CDG but not for ALG7–9. BioMed Central+1

1. Physiotherapy for hypotonia and contracture prevention – improves strength, posture, joint range; builds motor patterns through repetitive, task-specific training. CDG Hub

2. Occupational therapy – optimizes daily living (feeding, dressing), adapts tools, and provides hand–fine-motor work to enhance independence. CDG Hub

3. Speech-language therapy – supports swallowing safety and communication; early feeding strategies reduce aspiration and improve nutrition. CDG Hub

4. Feeding plans & texture modification – small, frequent feeds; thickened liquids for dysphagia?; coordinated with dietitians to meet calories/protein. CDG Hub

5. Nutrition optimization – energy-dense meals; manage protein-losing enteropathy; avoid prolonged fasting to stabilize energy needs. CDG Hub

6. Respiratory physiotherapy – airway clearance, positioning, and suction training reduce infection? burden. CDG Hub

7. Seizure? safety education – rescue plans, sleep hygiene, and triggers avoidance complement antiseizure drugs. National Organization for Rare Disorders

8. Vision services – regular eye checks; low-vision supports if cataracts or ocular issues present (ALG8). BioMed Central

9. Hearing evaluation and aids – address communication and learning early if hearing is affected. National Organization for Rare Disorders

10. Orthotics & mobility aids – ankle–foot orthoses, seating systems, standers; prevent deformity and improve participation. CDG Hub

11. Behavioral and educational supports – individualized education plans for developmental or autism-spectrum features (reported in ALG8 cohorts). PMC

12. GERD positioning & sleep positioning – upright after feeds; head elevation; reduces reflux and aspiration risk. CDG Hub

13. Skin and edema? care – compression and skincare when ascites/edema? present (ALG8). BioMed Central

14. Vaccination on time – prevents severe infections that can destabilize fragile infants. National Organization for Rare Disorders

15. Family genetic counseling – explains inheritance, carrier testing, and reproductive options. National Organization for Rare Disorders

16. Psychosocial support & CDG community resources – links to CDG Hub/CDG CARE; reduces caregiver burden. CDG Hub

17. Regular dental care – feeding difficulties and reflux raise dental risk; preventive care matters. National Organization for Rare Disorders

18. Thermoregulation and hydration plans during illness to prevent decompensation. National Organization for Rare Disorders

19. Sleep scheduling & melatonin hygiene strategies (with/without medication) to stabilize routines. National Organization for Rare Disorders

20. Specialist center follow-up – coordinated clinics (e.g., Mayo CDG clinic) provide integrated care. Mayo Clinic

Drug treatments

Important: Doses below are typical clinical ranges and must be individualized by a specialist. Many uses here are off-label in rare diseases.

1. Pyridostigmine (cholinesterase inhibitor) – for DPAGT1-related congenital? myasthenic weakness?.
   Class: Anticholinesterase. Dose: adults 30–60 mg PO q6–8 h; pediatrics often 0.5–1 mg/kg/dose q6–8 h. When: daytime doses, titrate to function. Purpose/Mechanism: increases acetylcholine at the neuromuscular junction to improve transmission compromised by under-glycosylated synaptic proteins. Side effects: cramps, diarrhea?, bradycardia?. PubMed

2. Levetiracetam – for seizures.
   Class: Antiseizure. Dose: 10–60 mg/kg/day divided. Purpose: reduces neuronal hyperexcitability. Side effects: irritability, somnolence. PMC

3. Valproate – for generalized seizures (avoid if significant liver disease).
   Class: Antiseizure. Dose: 20–60 mg/kg/day. Side effects: hepatotoxicity risk, platelet? count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia?—use caution in CDG with liver/coagulation issues. National Organization for Rare Disorders

4. Topiramate – adjunct for refractory epilepsy.
   Class: Antiseizure. Dose: 3–9 mg/kg/day. Side effects: appetite loss, acidosis, kidney stones. National Organization for Rare Disorders

5. Baclofen – spasticity or dystonia.
   Class: GABA-B agonist. Dose: start low (e.g., 5 mg TID adults; peds 0.5 mg/kg/day divided); titrate. Side effects: sedation, hypotonia. National Organization for Rare Disorders

6. Diazepam – intermittent spasticity relief or seizure? rescue (per protocol).
   Class: Benzodiazepine. Side effects: sedation, respiratory depression. National Organization for Rare Disorders

7. Omeprazole – reflux management to protect esophagus and nutrition.
   Class: PPI. Dose: 0.7–3.3 mg/kg/day. Side effects: diarrhea?, low Mg with chronic? use. National Organization for Rare Disorders

8. H2 blocker (ranitidine/famotidine alternatives) – if PPI not tolerated. Side effects: headache?, diarrhea?. National Organization for Rare Disorders

9. Prokinetic (erythromycin low-dose) – delayed gastric emptying; monitor QT. National Organization for Rare Disorders

10. Loperamide – protein-losing enteropathy/diarrhea (careful in young children; specialist oversight).
    Class: antimotility. Side effects: constipation. National Organization for Rare Disorders

11. Pancreatic enzymes – trial if malabsorption suspected; improve nutrient uptake. National Organization for Rare Disorders

12. Vitamin K – coagulopathy support when PT/INR prolonged. Dose: per coagulation specialist. Side effects: rare anaphylactoid with IV. National Organization for Rare Disorders

13. Fresh frozen plasma / specific factor concentrates – for significant bleeding/clotting events under hematology care. National Organization for Rare Disorders

14. Albumin infusion – severe hypoalbuminemia/edema with diuretics as needed; balances oncotic pressure. National Organization for Rare Disorders

15. Diuretics (spironolactone/furosemide) – ascites/edema management; monitor electrolytes/renal function. National Organization for Rare Disorders

16. Antibiotics per culture – treat bacterial infections promptly due to fragile reserves. National Organization for Rare Disorders

17. Melatonin – sleep regulation to support seizure control and development. Dose: 1–5 mg HS (child-specific guidance). Side effects: morning drowsiness. National Organization for Rare Disorders

18. Acetaminophen – pain/fever; prefer over NSAIDs when liver status allows careful dosing; avoid overdosing. National Organization for Rare Disorders

19. Carnitine (prescription-grade) – if low on labs; supports fat oxidation/energy. (Also see supplements.) National Organization for Rare Disorders

20. Antiepileptic rescue meds (buccal midazolam/rectal diazepam) – emergency seizure plans as directed. National Organization for Rare Disorders

Note on sugar therapies: Oral D-mannose is effective for MPI-CDG, not for ALG7–9; emerging research explores mannose-1-phosphate liposomes for other CDGs but they are experimental. PubMed+2PMC+2

Dietary molecular supplements

1. Coenzyme Q10 (e.g., 5–10 mg/kg/day) – supports mitochondrial electron transport; may help fatigue. Side effects: GI upset. National Organization for Rare Disorders

2. Riboflavin (B2) (5–20 mg/day child-dependent) – cofactor for energy enzymes; can improve fatigue. Harmless urine yellowing. National Organization for Rare Disorders

3. Thiamine (B1) (10–50 mg/day) – supports carbohydrate metabolism; may aid energy in hypotonia. National Organization for Rare Disorders

4. L-Carnitine (50–100 mg/kg/day divided) – shuttles fatty acids; consider if low on labs. GI upset possible. National Organization for Rare Disorders

5. Vitamin D (per serum level) – bone/immune support; deficiency is common. National Organization for Rare Disorders

6. Omega-3 fatty acids (EPA/DHA 50–100 mg/kg/day) – anti-inflammatory, may help neurodevelopment modestly. National Organization for Rare Disorders

7. Zinc (as needed per labs) – supports growth and immunity; excess causes copper deficiency. National Organization for Rare Disorders

8. Magnesium – for cramps or constipation; dose individualized. National Organization for Rare Disorders

9. Multivitamin with minerals – backstop for feeding difficulties or restricted diets. National Organization for Rare Disorders

10. Probiotics – may help diarrhea; choose child-safe strains and monitor response. National Organization for Rare Disorders

(These do not “cure” CDG; they support energy, growth, and symptom control.)

Regenerative / stem-cell” drug concepts

There are no approved regenerative or stem-cell drugs for ALG7–9 CDG. Below are investigational concepts you may encounter in the literature; dosing belongs only in clinical trials.

1. Gene therapy (AAV) concepts for DPAGT1/ALG8/ALG9 to restore enzyme—preclinical stage for several CDGs; not yet available clinically. ScienceDirect

2. Pharmacological chaperones/proteostasis modulators to stabilize misfolded enzymes (e.g., approaches explored in other CDGs like PMM2). Frontiers

3. Substrate or activated-sugar replacement (e.g., mannose-1-phosphate liposomes) being tested in cell/early translational studies. ScienceDirect

4. mRNA therapy to transiently supply the missing enzyme—conceptual stage for ultra-rare metabolic disorders. ScienceDirect

5. Hepatocyte or stem-cell transplantation for predominant liver disease (established only for select CDGs like MPI-CDG in severe cases). BioMed Central

6. Immune support via standard vaccination/IVIG only if a documented immunoglobulin deficiency is present (not routine in ALG7–9). National Organization for Rare Disorders

Surgeries

1. Gastrostomy tube placement – if unsafe swallow or failure to thrive; ensures safe, reliable nutrition/hydration. CDG Hub

2. Anti-reflux surgery (fundoplication) – for life-threatening reflux/aspiration that fails medical therapy. National Organization for Rare Disorders

3. Hernia repair – if present and symptomatic (some CDG infants develop hernias). National Organization for Rare Disorders

4. Strabismus/cataract surgery – to improve alignment or remove visually significant lenses (ALG8-linked cataracts). BioMed Central

5. Orthopedic procedures (tendon release/scoliosis correction) – for fixed contractures or severe spinal curves that impair care or breathing. National Organization for Rare Disorders

Prevention strategies

1. Accurate genetic diagnosis and family carrier testing to inform future pregnancies. National Organization for Rare Disorders

2. Genetic counseling for reproductive options (PGT, prenatal testing). National Organization for Rare Disorders

3. Avoid prolonged fasting; use sick-day plans to maintain hydration/calories. CDG Hub

4. On-time vaccinations (including influenza/RSV per local guidance). National Organization for Rare Disorders

5. Early therapy enrollment (PT/OT/SLP) to prevent secondary disability. CDG Hub

6. Aggressive treatment of infections to avoid decompensation. National Organization for Rare Disorders

7. Routine monitoring (liver, coagulation, nutrition, kidneys in ALG9) to catch complications early. PMC

8. Safe-swallow strategies to prevent aspiration pneumonia. CDG Hub

9. Dental and reflux management to protect teeth and growth. National Organization for Rare Disorders

10. Link with CDG centers and patient groups for protocols and trials. Mayo Clinic+1

When to see a doctor urgently

• Any new or worsening seizures, prolonged events, or behavior change after a seizure. PMC

• Signs of dehydration or persistent vomiting/diarrhea. Orpha.net

• Worsening edema/ascites, black stools, or bleeding/bruising. BioMed Central

• Breathing difficulty, recurrent chest infections, or choking during feeds. National Organization for Rare Disorders

• Sudden weakness, severe fatigue, or ptosis in known DPAGT1-CMS (may need medication adjustment). PubMed

What to eat and what to avoid

• Aim for energy-dense, protein-adequate meals in small, frequent portions; work with a metabolic dietitian. CDG Hub

• Thicken liquids if advised after a swallow study; soft/pureed textures if chewing is weak. CDG Hub

• Keep hydration steady, especially during illness; use oral rehydration solutions as guided. National Organization for Rare Disorders

• Avoid prolonged fasting (overnight and during illness). CDG Hub

• Consider MCT-rich options if fat malabsorption is suspected (dietitian-led). National Organization for Rare Disorders

• Avoid alcohol and unnecessary NSAIDs in adolescents/adults with liver involvement. National Organization for Rare Disorders

• No self-start sugar therapies (e.g., mannose) unless your CDG subtype is MPI-CDG and the clinic prescribes it. PubMed+1

Frequently asked questions (FAQs)

1. Is there a cure?
   Not yet for ALG7/8/9. Most care is supportive. D-mannose helps MPI-CDG, not ALG7–9. Research on substrate replacement (e.g., mannose-1-phosphate), chaperones, and gene therapy is ongoing. BioMed Central+1

2. How common is it?
   These are ultra-rare; only a handful to a few dozen patients are reported for ALG8 and ALG9; DPAGT1-CDG is also rare. BioMed Central+1

3. What’s different among “7, 8, 9”?
   They disrupt different steps of the same assembly-line: DPAGT1 starts the chain, ALG8 adds glucose late, ALG9 adds mannose in two steps. This partly explains overlapping—but not identical—symptoms. Wiley Online Library+2PubMed+2

4. Why are seizures common?
   Under-glycosylated neuronal proteins alter brain development and excitability. PMC

5. Why do some children have liver and clotting problems?
   Many liver-made proteins (albumin, clotting factors) require proper glycosylation to function and circulate. National Organization for Rare Disorders

6. What is the key screening test?
   Transferrin IEF or HPLC—then confirm by genetic testing. Nature

7. Can kidney cysts be part of this?
   Yes, ALG9-CDG has been linked with polycystic kidneys in published cases. PMC

8. Is cataract surgery ever needed?
   Sometimes in ALG8-CDG when cataracts are visually significant. BioMed Central

9. Are there special neuromuscular treatments?
   Yes. In DPAGT1-related myasthenia, pyridostigmine may help muscle strength. PubMed

10. Should families consider genetics counseling?
    Strongly recommended for carrier testing and future pregnancy planning. National Organization for Rare Disorders

11. Do special diets cure these CDGs?
    No. Diet supports growth and reduces complications, but it doesn’t fix the enzyme defect. Mannose therapy is subtype-specific (MPI-CDG). PubMed

12. What specialists are involved?
    Genetics/metabolic, neurology, gastro/hepatology, nutrition, PT/OT/SLP, and sometimes cardiology/nephrology/ophthalmology; multidisciplinary clinics exist. Mayo Clinic

13. What is the long-term outlook?
    Highly variable—depends on subtype and severity. Early supportive care improves growth and function. National Organization for Rare Disorders

14. Are clinical trials available?
    Trials emerge sporadically; check CDG centers and registries (CDG Hub, FCDGC). CDG Hub

15. What should we do during illness?
    Follow a sick-day plan: maintain fluids/calories, treat fevers/infections early, and seek medical review for dehydration or seizures. National Organization for Rare Disorders

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.